Filters: Keyword is Buprenorphine [Clear All Filters]
"Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence." Journal of substance abuse treatment 33, no. 4 (2007): 411-5. Abstract
"Utility of crossover designs in clinical trials: efficacy of desipramine vs. placebo in opioid-dependent cocaine abusers." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 11, no. 2 (2002): 111-23. Abstract
"Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone." Journal of addiction medicine 6, no. 4 (2012): 274-9. Abstract
"Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial." Addictive behaviors 35, no. 5 (2010): 537-40. Abstract
"A trial of integrated buprenorphine/naloxone and HIV clinical care." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S184-90. Abstract
"Treatment of heroin dependence with buprenorphine in primary care." The American journal of drug and alcohol abuse 28, no. 2 (2002): 231-41. Abstract
"Treatment of adolescent opioid dependence: no quick fix." JAMA : the journal of the American Medical Association 300, no. 17 (2008): 2057-9.
"Training HIV physicians to prescribe buprenorphine for opioid dependence." Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse 27, no. 3 (2006): 13-8. Abstract
"Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone." The American journal of drug and alcohol abuse 37, no. 4 (2011): 224-8. Abstract
"Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir." AIDS (London, England) 20, no. 5 (2006): 783-4.
"Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients." Drug and alcohol dependence 118, no. 2-3 (2011): 326-34. Abstract
"A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice." Expert review of clinical pharmacology 6, no. 3 (2013): 249-69. Abstract
"Provider satisfaction with office-based treatment of opioid dependence: a systematic review." Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse 26, no. 1 (2005): 15-22. Abstract
"Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients." Journal of general internal medicine 22, no. 4 (2007): 527-30. Abstract
"The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?" Drug and alcohol dependence 79, no. 1 (2005): 113-6. Abstract
"The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S178-83. Abstract
"A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners." Journal of opioid management 4, no. 2 (2008): 81-6. Abstract
"The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment." Journal of general internal medicine 25, no. 9 (2010): 936-41. Abstract
"Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone." Drug and alcohol dependence 105, no. 3 (2009): 234-9. Abstract
"Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir." Journal of acquired immune deficiency syndromes (1999) 54, no. 5 (2010): 511-4. Abstract
"Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice." Journal of acquired immune deficiency syndromes (1999) 41, no. 5 (2006): 563-72. Abstract
"Patient satisfaction with primary care office-based buprenorphine/naloxone treatment." Journal of general internal medicine 22, no. 2 (2007): 242-5. Abstract
"Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S14-21. Abstract
"Oral substitution treatment of injecting opioid users for prevention of HIV infection." Cochrane database of systematic reviews (Online), no. 8 (2011): CD004145. Abstract
"Opioid dependence: rationale for and efficacy of existing and new treatments." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S173-7. Abstract
"Opioid Dependence Treatment in the Emergency Department--Reply." JAMA 314, no. 8 (2015): 835.
"Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches?" CNS drugs 22, no. 2 (2008): 99-111. Abstract
"New challenges and opportunities in managing substance abuse in Malaysia." Drug and alcohol review 25, no. 5 (2006): 473-8. Abstract
"Narrative review: buprenorphine for opioid-dependent patients in office practice." Annals of internal medicine 148, no. 9 (2008): 662-70. Abstract
"Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine." American journal of preventive medicine 44, no. 1 Suppl 2 (2013): S86-90.
"Models for integrating buprenorphine therapy into the primary HIV care setting." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 42, no. 5 (2006): 716-21. Abstract
"Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence." The American journal of psychiatry 162, no. 2 (2005): 340-9. Abstract
"Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial." Lancet 371, no. 9631 (2008): 2192-200. Abstract
"Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 17, no. 2 (2008): 116-20. Abstract
"Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market." The American journal of drug and alcohol abuse 35, no. 2 (2009): 68-72. Abstract
"Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S235-46. Abstract
"Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S224-34. Abstract
"Interaction between buprenorphine and atazanavir or atazanavir/ritonavir." Drug and alcohol dependence 91, no. 2-3 (2007): 269-78. Abstract
"Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S68-75. Abstract
"Integration of buprenorphine for substance-abuse treatment by HIV care providers." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S1-2.
"Integrating buprenorphine treatment into office-based practice: a qualitative study." Journal of general internal medicine 24, no. 2 (2009): 218-25. Abstract
"Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes." Drug and alcohol dependence 131, no. 1-2 (2013): 127-35. Abstract
"Initial strategies for integrating buprenorphine into HIV care settings in the United States." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S191-6. Abstract
"Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S83-90. Abstract
"Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S39-45. Abstract
"Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment." Journal of urban health : bulletin of the New York Academy of Medicine 87, no. 4 (2010): 592-602. Abstract
"The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S54-61. Abstract
"Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians." Journal of addiction medicine 6, no. 2 (2012): 159-65. Abstract
"HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S22-32. Abstract
